Findings from the phase 3 SIERRA study showed that Iomab-B was associated with a higher durable complete response rate vs ...

Bill Traverso and his family are advocating for pediatric cancer awareness after his granddaughter, Harper Thair, battled ...

Multiple sessions at ESMO Congress 2024 covered antibody-drug conjugates (ADCs), which are an emerging therapy that holds ...

Staying at Hope Lodge gives a sense of comfort and community to cancer patients and their caregivers, Taylor said. Not only ...

At only seven years old, Tabib was diagnosed with acute myeloid leukemia, a diagnosis that forever changed her life.

TC Biopharm (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, will be presenting at the ThinkEquity ...

PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced ...

Discover Blueprint Medicines' groundbreaking patent for crystalline forms of Compound (I), targeting GIST and AML treatments. Learn about its unique properties and methods!

An expert discussed the findings of the COMMANDS trial evaluating Reblozyl’s role in red blood cell transfusion independence ...

US FDA approves anti-CD38 therapy, Sarclisa in combo with standard-of-care treatment for adult patients with NDMM who are not eligible for transplant: Paris Tuesday, September 24, ...

Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor ...

For children with acute lymphoblastic leukemia (ALL), measurable residual disease (MRD) after the end of first consolidation ...